Xencor (XNCR) Reports Interim Data from an Ongoing Open-Label Phase 2 Study of XmAb5871 in IgG4-Related Disease
Tweet Send to a Friend
Xencor, Inc. (NASDAQ: XNCR) today announced interim data from an ongoing, open-label, pilot Phase 2 study of XmAb®5871 in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE